| Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 37156249无 PMCID | 2023-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.Ann Oncol | PMID 37179020无 PMCID | 2023-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.Am J Clin Dermatol | PMID 37184828PMC10184626 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.Lancet Haematol | PMID 37187198无 PMCID | 2023-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.Am J Clin Dermatol | PMID 37213005PMC10293387 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.Adv Ther | PMID 37258803无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant.Pharmaceut Med | PMID 37286927PMC10314845 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.J Geriatr Oncol | PMID 37290207无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 37290468无 PMCID | 2023-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of bisoprolol 5 mg plus amlodipine 5 mg in patients with hypertension uncontrolled on monotherapy with 5 mg of amlodipine, a phase III multicenter, randomized, double-blind, placebo-controlled clinical trial - the AMCOR study.Curr Med Res Opin | PMID 37300442无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.Target Oncol | PMID 37329423PMC10345079 | 2023-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.Lancet Oncol | PMID 37329889无 PMCID | 2023-Jul | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.Am J Sports Med | PMID 37345256无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.EBioMedicine | PMID 37354600PMC10320523 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study.Am J Sports Med | PMID 37366164无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.Clin Ther | PMID 37385905无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.Am J Cardiovasc Drugs | PMID 37395974PMC10328852 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.Radiology | PMID 37462494无 PMCID | 2023-Jul | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Efficacy and Safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Pedis: A Phase III Randomised, Double-Blind, Parallel-Group, Active-Controlled Study in Indian Adult Patients.Clin Drug Investig | PMID 37462803无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.CNS Drugs | PMID 37477771PMC10374812 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma - the ASCOT study.Health Technol Assess | PMID 37840322PMC10591211 | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.Lancet Rheumatol | PMID 38251552无 PMCID | 2023-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.N Engl J Med | PMID 37379135无 PMCID | 2023-Jun-29 | 0.45 | The study is a Phase 3 randomized trial of a drug (mirikizumab) for ulcerative colitis, which is not a malignant neoplasm (oncology). Although it meets criteria for being a human, randomized, Phase 3, original result report with a drug intervention, it fails the core oncology requirement. Additionally, no time-to-event efficacy endpoint was identified; the primary endpoints were categorical remission rates. | 待处理 |
| Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.Lancet | PMID 37302395无 PMCID | 2023-Jun-24 | 0.90 | The trial is eligible for oncology, human, randomized, and phase 3 status, but is excluded because it lacks a drug-containing intervention (it is a radiotherapy study) and the primary endpoint (ipsilateral breast tumor relapse) as reported is not a standard time-to-event efficacy endpoint like OS/PFS/DFS with Kaplan-Meier or HR. | 待处理 |
| Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet | PMID 37321235PMC10314240 | 2023-Jun-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.Vaccine | PMID 37244809PMC10165018 | 2023-Jun-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.N Engl J Med | PMID 37342922PMC10575613 | 2023-Jun-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol | PMID 36952634PMC10431499 | 2023-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).J Clin Oncol | PMID 36996380PMC10414728 | 2023-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.J Clin Oncol | PMID 37079878无 PMCID | 2023-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials.Scand J Urol | PMID 37338209无 PMCID | 2023-Jun-20 | 0.95 | The record describes a review of Phase III randomized trials comparing radiation fractionation schedules for prostate cancer. While it meets criteria for oncology, human subjects, randomization, and phase, it fails because the intervention is non-drug (radiation only) and no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, with KM or HR) is explicitly reported; the primary outcome is 'tumour control,' which is not defined as a time-to-event endpoint in the query. | 待处理 |
| Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).BMC Cancer | PMID 37337155PMC10278289 | 2023-Jun-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.J Clin Endocrinol Metab | PMID 36633570PMC10271225 | 2023-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.J Clin Endocrinol Metab | PMID 36639249PMC10271219 | 2023-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Cancer | PMID 37060236无 PMCID | 2023-Jun-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.Blood Adv | PMID 36848639PMC10241857 | 2023-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.J Clin Oncol | PMID 36917758无 PMCID | 2023-Jun-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.J Clin Oncol | PMID 37104723PMC10256387 | 2023-Jun-10 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.Lancet | PMID 37156252无 PMCID | 2023-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.Lipids Health Dis | PMID 37301827PMC10257163 | 2023-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial.Radiat Oncol | PMID 37365597PMC10294302 | 2023-Jun-09 | 0.45 | The record is from a Phase III randomized trial in human oncology (gastric cancer), but it reports only hematological toxicity and dosimetry parameters. It does not report survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes required for eligibility. Therefore, eligibility cannot be established from the provided metadata. | 待处理 |
| Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.N Engl J Med | PMID 36972022PMC10351614 | 2023-Jun-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.N Engl J Med | PMID 36972026无 PMCID | 2023-Jun-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.Sci Rep | PMID 37277418PMC10241804 | 2023-Jun-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 37075781无 PMCID | 2023-Jun-03 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.Lancet | PMID 37146623无 PMCID | 2023-Jun-03 | 0.95 | This is a phase 3 randomized trial in chronic low back pain, not oncology. The interventions are non-drug (Cognitive Functional Therapy, biofeedback). The primary endpoints are activity limitation (disability score) and QALYs, with no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) reported. | 待处理 |
| Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.Neuro Oncol | PMID 36472389PMC10237411 | 2023-Jun-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial.Eur J Anaesthesiol | PMID 36647565PMC10155686 | 2023-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).J Clin Oncol | PMID 36940407PMC10414734 | 2023-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.JAMA Neurol | PMID 37036722PMC10087094 | 2023-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |